Evommune
Evommune raises $50M Series B at $300M valuation
Quick Facts
Evommune: Series B Funding Round
Evommune has successfully raised $50M in Series B funding, reaching a valuation of $300M.
Company Overview
Oral immunology treatments
Funding Details
The Series B round was led by Arix Bioscience, with participation from EQT Life Sciences.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2021
- Employees: 70+
- Category: HealthTech
Investment
Evommune plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arix Bioscience: Verified investor in Series B
- EQT Life Sciences: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
